Atenolol 25 mg Tablet
Description
ATENOROOT 25
Atenolol 25 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Atenolol IP — 25 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
ATENOROOT 25 contains Atenolol 25 mg, a cardioselective beta-1 adrenergic receptor blocker formulated for the effective management of hypertension, angina pectoris, cardiac arrhythmias, and long-term cardiovascular protection. Atenolol provides sustained blood pressure control by reducing heart rate, myocardial contractility, cardiac output, and myocardial oxygen demand, making it an important therapeutic option in cardiovascular disease management.
Atenolol is widely prescribed in cardiology and internal medicine for patients with essential hypertension, chronic stable angina, supraventricular tachyarrhythmias, ischemic heart disease, post-myocardial infarction care, and cardiovascular risk reduction. It helps reduce systolic and diastolic blood pressure, control heart rate, decrease cardiac workload, and lower the risk of recurrent cardiovascular events.
ATENOROOT 25 is particularly beneficial for patients initiating beta-blocker therapy, elderly patients, individuals requiring lower-dose antihypertensive treatment, hypertension associated with tachycardia, coronary artery disease, and long-term cardiovascular protection.
Technical Knowledge of Atenolol
Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. This results in reduced myocardial oxygen demand, prolonged diastolic filling time, improved coronary perfusion, and effective control of blood pressure and heart rate.
Because of its cardioselective action, Atenolol primarily affects cardiac beta-1 receptors with less effect on beta-2 receptors compared with non-selective beta-blockers, making it suitable for many patients requiring long-term cardiovascular therapy.
Mechanism of Action
Atenolol selectively blocks beta-1 adrenergic receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, lowers myocardial oxygen demand, improves coronary perfusion, and provides sustained cardiovascular protection.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Reduces heart rate and myocardial workload
Provides sustained antihypertensive action
Supports long-term cardiovascular protection
Helps prevent chronic angina attacks
Controls supraventricular arrhythmias
Reduces the risk of recurrent cardiovascular events
Suitable for low-dose cardiovascular therapy
Convenient once-daily dosing
Suitable for long-term cardiovascular management under medical supervision
Clinical Applications
ATENOROOT 25 is commonly prescribed for essential hypertension, chronic stable angina, supraventricular tachyarrhythmias, ischemic heart disease, post-myocardial infarction management, hypertension with tachycardia, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Atenolol
Atenolol is a well-established cardioselective beta-blocker with extensive clinical experience in hypertension, angina, and cardiovascular disease management. It has demonstrated significant benefits in heart rate control, reduction of myocardial oxygen demand, blood pressure management, and prevention of recurrent cardiovascular events in appropriately selected patients. The 25 mg strength is particularly useful for therapy initiation, elderly patients, and patients requiring individualized dose titration.
Key Facts
Cardioselective beta-1 adrenergic blocker
Atenolol 25 mg for blood pressure and heart rate control
Reduces myocardial oxygen demand
Effective in hypertension, angina, and arrhythmias
Supports long-term cardiovascular protection
Evidence-based beta-blocker therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ATENOROOT 25 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose ATENOROOT 25 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Atenolol 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
ATENOROOT 25 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular protection, evidence-based beta-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Atenolol formulation.
